Comparative Pharmacokinetics and Pharmacodynamics of Doripenem and Meropenem in Obese Patients

Annals of Pharmacotherapy

Volumn 48, Issue 2, 2014, Pages 178-186

  Kays, Michael B ^a   Fleming, Megan R ^b   Cheatham, S Christian ^c   Chung, Eun Kyoung ^a   Juenke, Joetta M ^d  

^a PURDUE UNIVERSITY   (United States)

^b METHODIST DALLAS MEDICAL CENTER   (United States)

^c Franciscan St Francis Cancer Center   (United States)

^d ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

Author keywords

doripenem; meropenem; obesity; pharmacodynamics; pharmacokinetics

Indexed keywords

DORIPENEM; MEROPENEM;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; DRUG CLEARANCE; FEMALE; HOSPITAL PATIENT; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; OBESITY; PHARMACODYNAMICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STEADY STATE; STUDENT T TEST;

DORIPENEM; MEROPENEM; OBESITY; PHARMACODYNAMICS; PHARMACOKINETICS;

ADULT; ANTI-BACTERIAL AGENTS; CARBAPENEMS; FEMALE; GRAM-NEGATIVE BACTERIA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; OBESITY; THIENAMYCINS;

EID: 84893297945     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013512474     Document Type: Article

References (33)

1. World Health Organization. Obesity and Overweight. Geneva, Switzerland: WHO; 2012. Fact sheet No. 311. http://www.who.int/mediacentre/factsheets/fs311/en. Accessed August 29, 2013.
2. Food and Agriculture Organization. The State of Food and Agriculture: Foods Systems for Better Nutrition. Rome, Italy: FAO: 2013. http://www.fao.org/docrep/018/i3300e/i3300e.pdf. Accessed August 29, 2013.
3. Stevens GA,Singh GM,Lu Y,et al.National, regional, and global trends in adult overweight and obesity prevalences.Popul Health Metr. 2012;10:22.
4. Flegal KM,Carroll MD,Kit BK,Ogden CL.Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010.JAMA. 2012;307:483-490.
5. Mendes RE,Rhomberg PR,Bell JM,Turnidge JD,Sader HS.Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents.Diagn Microbiol Infect Dis. 2009;63:415-425.
6. Snydman DR,Jacobus NV,McDermott LA,et al.Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).Clin Infect Dis. 2010;50:S26-S33.
7. Davies TA,Queenan AM,Morrow BJ,et al.Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-2009.J Antimicrob Chemother. 2011;66:2298-2307.
8. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare associated pneumonia.Am J Respir Crit Care Med. 2005;171:388-416.
9. Chastre J,Wunderink R,Prokocimer P,Lee M,Kaniga K,Friedland I.Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.Crit Care Med. 2008;36:1089-1096.
10. Rea-Neto A,Niederman M,Lobo SM,et al.Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.Curr Med Res Opin. 2008;24:2113-2126.
11. Lodise TP,Lomaestro BM,Drusano GL.Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on β-lactam antibiotics.Pharmacotherapy. 2006;26:1320-1332.
12. Li C,Du X,Kuti JL,Nicolau DP.Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections.Antimicrob Agents Chemother. 2007;51:1725-1730.
13. Ariano RE,Nyhlen A,Donnelly JP,Sitar DS,Harding GKM,Zelenitsky.Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia.Ann Pharmacother. 2005;39:32-38.
14. Pai MP,Bearden DT.Antimicrobial dosing considerations in obese adult patients: insights from the Society of Infectious Diseases Pharmacists.Pharmacotherapy. 2007;27:1081-1091.
15. Janson B,Thursky K.Dosing of antibiotics in obesity.Curr Opin Infect Dis. 2012;25:634-649.
16. Chen M,Nafziger AN,Drusano GL,Ma L,Bertino JS.Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults.Antimicrob Agents Chemother. 2006;50:1222-1227.
17. Hites M,Taccone FS,Wolff F,et al.Case-control study of drug monitoring of β-lactams in obese critically ill patients.Antimicrob Agents Chemother. 2013;57:708-715.
18. Demirovic JA,Pai AB,Pai MP.Estimation of creatinine clearance in morbidly obese patients.Am J Health Syst Pharm. 2009;66:642-648.
19. Gibaldi M,Perrier DPharmacokinetics. New York, NY: Marcel Dekker; 1982:.
20. DeRyke CA,Kuti JL,Nicolau DP.Pharmacodynamic target attainment of six β-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004.Pharmacotherapy. 2007;27:333-342.
21. Koomanachai P,Bulik CC,Kuti JL,Nicolau DP.Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.Clin Ther. 2010;32:766-779.
22. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Wayne, PA: CLSI; 2012:.
23. Jain R,Chung SM,Jain L,et al.Implications of obesity for drug therapy: limitations and challenges.Clin Pharmacol Ther. 2011;90:77-89.
24. Falagas ME,Karageorgopoulos DE.Adjustment of dosing of antimicrobial agents for bodyweight in adults.Lancet. 2010;375:248-251.
25. Sturm AW,Allen N,Rafferty KD,et al.Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.Pharmacotherapy. In press;:.
26. Cirillo I,Vaccaro N,Turner K,Solanki B,Natarajan J,Redman R.Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers.J Clin Pharmacol. 2009;49:798-806.
27. Nandy P,Samtani MN,Lin R.Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies in critically ill patients.Antimicrob Agents Chemother. 2010;54:2354-2359.
28. Jaruratanasirikul S,Wongpoowarak W,Kositpantawong N,Aeinlang N,Jullangkoon M.Pharmacodynamics of doripenem in critically ill patients with ventilator-associated gram-negative bacilli pneumonia.Int J Antimicrob Agents. 2012;40:434-439.
29. Hanley MJ,Abernethy DR,Greenblatt DJ.Effect of obesity on the pharmacokinetics of drugs in humans.Clin Pharmacokinet. 2010;49:71-87.
30. Cheatham SC,Kays MB,Smith DW,Wack MF,Sowinski KM.Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients.Pharmacotherapy. 2008;28:691-698.
31. Thalhammer F,Traunmuller F,El Menyawi I,et al.Continuous infusion versus intermittent administration of meropenem in critically ill patients.J Antimicrob Chemother. 1999;43:523-527.
32. Kitzes-Cohen R,Farin D,Piva G,De Myttenaere-Bursztein SA.Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients.Int J Antimicrob Agents. 2002;19:105-110.
33. Novelli A,Adembri C,Livi P,Fallani S,Mazzei T,De Gaudio AR.Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis.Clin Pharmacokinet. 2005;44:539-549.